Cargando…

Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study

This cohort study assessed the pancreatic safety of vildagliptin versus other noninsulin antidiabetic drugs (NIADs) based on data from five European electronic health care databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Rachael, Kothny, Wolfgang, Serban, Carmen, Lopez‐Leon, Sandra, Schlienger, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458459/ https://www.ncbi.nlm.nih.gov/pubmed/31008361 http://dx.doi.org/10.1002/edm2.52

Ejemplares similares

Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study
por: Williams, Rachael, et al.
Publicado: (2019)

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
por: Antinori, Andrea, et al.
Publicado: (2016)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Odawara, Masato, et al.
Publicado: (2015)

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
por: Lukashevich, Valentina, et al.
Publicado: (2013)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
por: Kothny, Wolfgang, et al.
Publicado: (2015)

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes
por: Lo Re, Vincent, et al.
Publicado: (2017)

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
por: Kozlovski, Plamen, et al.
Publicado: (2017)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A
por: Motwani, Jayashree, et al.
Publicado: (2020)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial
por: Ziemssen, Focke, et al.
Publicado: (2020)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
por: Pan, CY, et al.
Publicado: (2013)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
por: Aziz, Kamran MA
Publicado: (2015)

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study
por: Martín Algarra, Salvador, et al.
Publicado: (2017)

Acute Pancreatitis in Pregnancy: A Ten-Year Noninterventional, Retrospective Cohort Experience
por: Haiyan, Zhao, et al.
Publicado: (2022)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
por: Broadwell, Aaron, et al.
Publicado: (2023)

The safety profile of parecoxib for the treatment of postoperative pain: a pooled analysis of 28 randomized, double-blind, placebo-controlled clinical trials and a review of over 10 years of postauthorization data
por: Schug, Stephan A, et al.
Publicado: (2017)

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
por: Chakraborti, C.K.
Publicado: (2008)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
por: Mathieu, Chantal, et al.
Publicado: (2008)

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Profit, Louise, et al.
Publicado: (2008)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study
por: Heinemann, Klaas, et al.
Publicado: (2020)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
por: Hirose, Takahisa, et al.
Publicado: (2015)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study
por: Pavicic, Tatjana, et al.
Publicado: (2015)

Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2d2qnunc5k40mqc7pjj3hfe007